ÌìÃÀÓ°Ôº

Summary: Every clinical study is different, each with its own unique characteristics and requirements. The optimal time to begin planning a clinical supply strategy is while the study...

Summary: A well-known, mid-size, multi-national pharmaceutical company needed a large supply of comparator drug, in order to begin comparative clinical trials for a rare disease. In addition to quantity, the comparator drug must have an expiry-term long enough for the client to complete the multi-year clinical trials...

Summary: This case study explores ÌìÃÀӰԺ’s unique GPEx® technology for stable gene product expression with Berkeley Lights, Inc.’s (BLI) Beacon® instrument for clonal selection.

Learn how a biopharmaceutical company partnered with ÌìÃÀÓ°Ôº to develop and manufacture a commercially-viable, patient-friendly, stable tablet for a program intended to treat a disease that has unmet medical need.

Learn what clinical sponsors should look for when assessing integrated services and potential providers.

While clinical studies are in Phase 2, it is important for sponsors to be prepared for any Phase 3 challenges that might arise. Understanding what resources are available is key to being ready for Phase 3 before it even begins.

Summary: In this executive summary, industry experts share case studies of how they’ve adapted to increasingly expedited regulatory reviews.

Summary: As the need for accelerated biopharmaceutical development around the world continues to grow,  companies are facing complex challenges that need to be overcome to remain competitive for increasing process productivity...

Summary: A ÌìÃÀÓ°Ôº customer wanted to run a clinical trial in Israel and was arranging to ship their clinical trial product from a non-ÌìÃÀÓ°Ôº facility in Europe to a ÌìÃÀÓ°Ôº-managed and audited depot in Israel. With the protocol based...

Summary: MGB Biopharma, a biotech company based in Scotland, U.K. was developing a new class of anti-infective medicine based on Minor Groove Binder compounds. Learn how ÌìÃÀÓ°Ôº provided integrated formulation...